LabCorp's Drug Development Business, Covance, Acquires GlobalCare
LabCorp recently announced the company’s drug development business, Covance, has acquired GlobalCare, a globally recognized industry leader in patient-centric decentralized clinical trials support services.
This acquisition will expand Covance’s decentralized clinical trials capabilities globally, enabling recruitment and increasing access to trials. Specifically, Covance will leverage GlobalCare’s mobile healthcare services, site staffing support, patient transport assistance and contracted central pharmacy services, complementing and strengthening Covance’s decentralized trial capabilities.
This acquisition will benefit GlobalCare’s current and future customers by providing access to needed resources and technology to scale services to meet growing industry needs. GlobalCare will also complement its existing services with additional important decentralized clinical trial services via Covance capabilities such as eConsent, tele-health, Electronic Data Capture (EDC), online patient scheduling, connected device solutions, and more. This transaction allows for seamless integration of a full suite of biopharmaceutical services.
In November 2019, Covance launched its cohesive Decentralized Clinical Trials (DCT) solutions, which integrate unique capabilities from across the company’s leading diagnostic and drug development business units, redefining the patient experience to increase participation.
For more information about Covance and its DCT capabilities, click here.
For more information about GlobalCare, click here.
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
May 22nd 2025One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
